Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
Dear Guest, Your Attention Please:  


In the next days, the daily page limit for non-members will decrease to 20 pages to split up resources in favour of the MR-TIP Community. Beyond this limitation, most resources will still be available for everyone. If you want to join the MR-TIP Community, please register here.


 'Gadolinium' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadolinium' found in 4 terms [] and 63 definitions []
previous     26 - 30 (of 67)     next
Result Pages : [1]  [2 3 4 5 6 7 8 9 10 11 12 13 14]
Searchterm 'Gadolinium' was also found in the following services: 
spacer
News  (36)  Resources  (6)  Forum  (17)  
 
Pharmacyclics, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.pcyc.com Pharmacyclics is a pharmaceutical company developing novel agents to improve current therapeutic approaches to cancer, cardiovascular diseases, and inflammation. The company's proprietary products are derived from its core technology in biometallic chemistry. These products under development are based upon small molecules, which bind metals in a unique way and are capable of capturing and focusing forms of energy used in a variety of medical applications. The company has one product in registration with the FDA, Gadolite® Oral Suspension, a contrast agent for imaging the gastrointestinal tract; two products in clinical development, Gd-Tex (Motexafin gadolinium), a radiation sensitizer, Lu-Tex, a photosensitizer; and several compounds in preclinical development.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Gadolite® Oral Suspension
Motexafin Gadolinium

Contact Information
MAIL Pharmacyclics Inc.
995 East Arques Avenue
94085 Sunnyvale, California
USA
PHONE +1-408-774-0330
FAX +1-408-774-0340
E-MAIL info@pcyc.com
ONLINE www.pcyc.com
spacer

• View the NEWS results for 'Pharmacyclics, Inc.' (5).Open this link in a new window.
 
Further Reading:
  News & More:
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday, 21 December 2007   by www.prnewswire.com    
Texaphyrin Compounds Visualize Vulnerable Plaque
Friday, 4 June 2004   by www.hospimedica.com    
Searchterm 'Gadolinium' was also found in the following service: 
spacer
Radiology  (1) Open this link in a new window
ProHance®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
ProHance® consists of a nonionic gadolinium complex (Gadoteridol) used as a paramagnetic MR contrast agent.
ProHance® provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. ProHance® can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See Gadoteridol.

Drug Information and Specification
NAME OF COMPOUND Gadoteridol, Gd-HP-DO3A
DEVELOPER Bracco Diagnostics
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.7, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 630 mosm/kgH2O
CONCENTRATION 0.5 mol/L, 279.3mg/ml
DOSAGE 0.1 mmol Gd/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15 and 20 mL
Glass syringes of 5, 10, 15 and 17 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA
EU
ProHance® for sale Bracco Diagnostics
Australia ProHance® for sale Bracco Pty Ltd
Japan ProHance® for sale Bracco-Eisai Co., Ltd

spacer

• View the DATABASE results for 'ProHance®' (6).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
Prohance Product Information
   by www.drugs.com    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
PACS - Devices - Blood Flow Imaging - Software - Education pool - Image Quality
 
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

Drug Information and Specification
NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
DEVELOPER EPIX Pharmaceuticals, Inc.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY 20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC Intravascular
OSMOLALITY 825 mOsmol/kg H2O
CONCENTRATION 244 mg/mL, 0.25mmol/mL
DOSAGE 0.12 mL/kg, 0.03 mmol/kg
PREPARATION ready to use
INDICATION Contrast enhanced magnetic resonance angiography
DEVELOPMENT STAGE FDA approved
DISTRIBUTOR See below
PRESENTATION 10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Vasovist™ Approved ?
USA, Canada, Australia ABLAVAR™ Approved Lantheus Medical Imaging, Inc.

spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
Searchterm 'Gadolinium' was also found in the following services: 
spacer
News  (36)  Resources  (6)  Forum  (17)  
 
B-19036InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: B-19036, central moiety: Gd+
B19036/7 compared with E-7155, Gd-BOPTA, Gd-BOPTA/Dimeg are synonyms for the contrast agent MultiHance®, marketed by Bracco Diagnostics Inc, Milan, Italy. B-19036 is a gadolinium chelate. See also the contrast agent info sheet about classifications, characteristics, etc.
spacer
 
Further Reading:
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
Searchterm 'Gadolinium' was also found in the following service: 
spacer
Radiology  (1) Open this link in a new window
B22956InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: B22956, generic name: Gadocoletic acid, chemical compound: Gadocoletic acid trisodium salt, central moiety: Gd, phase: II
A blood pool agent for magnetic resonance coronary angiography and first pass myocardial perfusion imaging under development (Bracco Diagnostics Inc). The small molecules of gadolinium-based B22956 are bound after injection to large human serum albumin molecules in coronary vessels with the result of high vessel/muscle contrast.

spacer

• View the DATABASE results for 'B22956' (2).Open this link in a new window

MRI Resources 
Brain MRI - Pregnancy - Education - Societies - Fluorescence - Collections
 
previous      26 - 30 (of 67)     next
Result Pages : [1]  [2 3 4 5 6 7 8 9 10 11 12 13 14]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Your MRI scanner(s) in 5 years should be :
more automated 
much quicker 
quiet 
voice controlled 
iPhone compatible 
as it is right now 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 22 January 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]